{
    "id": 90,
    "premise": "none",
    "hypothesis": "Olaparib and talazoparib are licensed PARP inhibitors, which target tumour specific defects in DNA repair.",
    "label": "entailment",
    "explanation": "[PARP1/2] inhibitors target tumour-specific defects in DNA repair through the role of PARP1/2 in recover from DNA damage.\nolaparib and talazoparib are licensed poly [ADP-ribose] polymerase 1/2 inhibitors.",
    "results": {
        "semantic validity": true,
        "premise": null,
        "hypothesis": "Olaparib and talazoparib are licensed PARP inhibitors, which target tumour specific defects in DNA repair.",
        "refined explanation": "[PARP1/2] inhibitors target tumour-specific defects in DNA repair through the role of PARP1/2 in recover from DNA damage.\nolaparib and talazoparib are licensed poly [ADP-ribose] polymerase 1/2 inhibitors.",
        "refined iteration": 0,
        "history explanation": [
            "0 iteration: [PARP1/2] inhibitors target tumour-specific defects in DNA repair through the role of PARP1/2 in recover from DNA damage.\nolaparib and talazoparib are licensed poly [ADP-ribose] polymerase 1/2 inhibitors."
        ],
        "history semantic validity": [
            "0 iteration: True"
        ],
        "history critique output": [
            "0 iteration: {'syntactic validity': True, 'error code': '', 'solving time': 10.756736516952515, 'proof tactics': ['Sledgehammering...', 'zipperposition found a proof...', 'cvc4 found a proof...', 'e found a proof...', 'vampire found a proof...', 'zipperposition: Try this: using explanation_1 explanation_2 by blast (5 ms)', 'cvc4: Found duplicate proof', 'e: Found duplicate proof', 'zipperposition found a proof...', 'vampire: Found duplicate proof', 'zipperposition: Found duplicate proof', 'Done'], 'code': 'theory clinical_90_0\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  PARPInhibitor :: \"entity \u21d2 bool\"\\n  Target :: \"event \u21d2 entity \u21d2 bool\"\\n  TumourSpecificDefects :: \"event \u21d2 bool\"\\n  DNARepair :: \"event \u21d2 bool\"\\n  RoleOf :: \"event \u21d2 entity \u21d2 bool\"\\n  RecoverFromDamage :: \"event \u21d2 bool\"\\n  Olaparib :: \"entity \u21d2 bool\"\\n  Talazoparib :: \"entity \u21d2 bool\"\\n  Licensed :: \"entity \u21d2 bool\"\\n  PolyADPInhibitor :: \"entity \u21d2 bool\"\\n  Polymerase12Inhibitor :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: [PARP1/2] inhibitors target tumour-specific defects in DNA repair through the role of PARP1/2 in recover from DNA damage. *)\\naxiomatization where\\n  explanation_1: \"\u2200x e. PARPInhibitor x \u2227 Target e x \u2227 TumourSpecificDefects e \u2227 DNARepair e \u2227 RoleOf e PARP1 \u2227 RecoverFromDamage e\"\\n\\n(* Explanation 2: Olaparib and talazoparib are licensed poly [ADP-ribose] polymerase 1/2 inhibitors. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y. Olaparib x \u2227 Talazoparib y \u2227 Licensed x \u2227 Licensed y \u2227 PolyADPInhibitor x \u2227 PolyADPInhibitor y \u2227 Polymerase12Inhibitor x \u2227 Polymerase12Inhibitor y\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"PARPInhibitor x \u2227 PARPInhibitor y \u2227 Licensed x \u2227 Licensed y\"\\n  (* Hypothesis: Olaparib and talazoparib are licensed PARP inhibitors, which target tumour specific defects in DNA repair. *)\\n shows \"\u2203x y e. Olaparib x \u2227 Talazoparib y \u2227 Licensed x \u2227 Licensed y \u2227 PARPInhibitor x \u2227 PARPInhibitor y \u2227 Target e x \u2227 Target e y \u2227 TumourSpecificDefects e \u2227 DNARepair e\"\\nproof -\\n  (* From the premise, we have the information about PARPInhibitor x, PARPInhibitor y, Licensed x, and Licensed y. *)\\n  from asm have \"PARPInhibitor x\" and \"PARPInhibitor y\" and \"Licensed x\" and \"Licensed y\" <ATP>\\n  (* We know that there is an equivalence between being licensed and being a poly [ADP-ribose] polymerase 1/2 inhibitor. *)\\n  (* There is a logical relation Implies(C, D), Implies(olaparib and talazoparib are licensed, poly [ADP-ribose] polymerase 1/2 inhibitors) *)\\n  (* Since we have Licensed x and Licensed y, we can infer that Olaparib x and Talazoparib y are poly [ADP-ribose] polymerase 1/2 inhibitors. *)\\n  then have \"PolyADPInhibitor x\" and \"PolyADPInhibitor y\" and \"Polymerase12Inhibitor x\" and \"Polymerase12Inhibitor y\" <ATP>\\n  (* We have the explanatory sentence 1 stating that PARPInhibitors target tumour-specific defects in DNA repair through the role of PARP1/2 in recover from DNA damage. *)\\n  (* This implies that PARPInhibitors are related to targeting tumour-specific defects in DNA repair and the role of PARP1/2 in recover from DNA damage. *)\\n  (* We can infer that PARPInhibitor x and PARPInhibitor y are related to targeting tumour-specific defects in DNA repair and the role of PARP1/2 in recover from DNA damage. *)\\n  then have \"Target e x\" and \"Target e y\" and \"TumourSpecificDefects e\" and \"DNARepair e\" <ATP>\\n  (* Combining all the information, we can conclude that Olaparib x, Talazoparib y, Licensed x, Licensed y, PARPInhibitor x, PARPInhibitor y, Target e x, Target e y, TumourSpecificDefects e, and DNARepair e hold. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: [PARP1/2] inhibitors target tumour-specific defects in DNA repair\\nB: the role of PARP1/2 in recover from DNA damage\\nC: olaparib and talazoparib are licensed\\nD: poly [ADP-ribose] polymerase 1/2 inhibitors\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies([PARP1/2] inhibitors target tumour-specific defects in DNA repair, the role of PARP1/2 in recover from DNA damage)\\n--------\\nEquivalent(C, D)\\nEquivalent(olaparib and talazoparib are licensed, poly [ADP-ribose] polymerase 1/2 inhibitors)\\n--------\\n\\nDerived Implications:\\nImplies(Not(C), Not(D))\\nImplies(Not(olaparib and talazoparib are licensed), Not(poly [ADP-ribose] polymerase 1/2 inhibitors))\\n--------\\nImplies(C, D)\\nImplies(olaparib and talazoparib are licensed, poly [ADP-ribose] polymerase 1/2 inhibitors)\\n--------\\nImplies(D, C)\\nImplies(poly [ADP-ribose] polymerase 1/2 inhibitors, olaparib and talazoparib are licensed)\\n--------\\nImplies(Not(D), Not(C))\\nImplies(Not(poly [ADP-ribose] polymerase 1/2 inhibitors), Not(olaparib and talazoparib are licensed))\\n--------\\n'}"
        ]
    }
}